ライフサイエンスコーパス: risk stratification

1 necessitating an individualized approach to risk stratification.

2 ors to be considered in sudden cardiac death risk stratification.

3 up of tumors, and provide new parameters for risk stratification.

4 using 21 comprehensive baseline indices for risk stratification.

5 gnosis independent of clinical and biomarker risk stratification.

6 c risk model m7FLIPI, are important tools in risk stratification.

7 cardiology to improve disease diagnosis and risk stratification.

8 nical and genetic predictors may improve HCC risk stratification.

9 n clinical care to enable accurate and rapid risk stratification.

10 prognostic information to current methods of risk stratification.

11 and after adjustment (P = .01) for baseline risk stratification.

12 esent attractive biomarkers for personalized risk stratification.

13 cal severity in affected individuals and for risk stratification.

14 and then using this information for post-KT risk stratification.

15 regarding duration of monitoring based on ED risk stratification.

16 ding of arrhythmia mechanisms and challenges risk stratification.

17 ce of CA, provided robust hospital mortality risk stratification.

18 risk stratification approaches, can improve risk stratification.

19 encing, to identify molecular biomarkers for risk stratification.

20 using mostly generic medicines and optimized risk stratification.

21 identification of meaningful thresholds for risk stratification.

22 y and Intervention (SCAI) for the purpose of risk stratification.

23 well but give different optimal cutoffs for risk stratification.

24 evaluation to admission may improve post-KT risk stratification.

25 sis-affected households might be improved by risk stratification.

26 Combining hs-TnI with BNP helped better risk stratification.

27 re, uNGAL is a useful tool for improving AKI risk stratification.

28 trate for arrhythmias is crucial for optimal risk stratification.

29 ant considerations for personalized care and risk stratification.

30 s for SGA in Brazil and assess potential for risk stratification.

31 ude chemoprophylaxis based upon preoperative risk stratification.

32 ast cancer, representing a valuable tool for risk stratification.

33 ia including QRS fragmentation might improve risk stratification.

34 e gradient threshold of 31 mm Hg may improve risk stratification.

35 or a given BMI category, to optimize obesity risk stratification across age, sex and ethnicity.

36 s the guidelines' threshold of 35 ml/m(2) in risk stratification after AVR.

37 -up biopsies and DSA measurements to improve risk stratification after BKPyVAN, although prospective

38 We aimed to simplify the risk stratification after variceal bleeding using clinic

39 duction of the ICD associated with a matured risk stratification algorithm has altered management str

40 antially with the formulation of an enhanced risk stratification algorithm.

41 However, current risk stratification algorithms dichotomize variables and

42 These findings might allow for better risk stratification although outcomes are still poor.

43 culosis infection testing should be used for risk stratification among household contacts of patients

44 the future potential of polygenic scores for risk stratification among individuals with highly, but i

45 s in peripheral blood may allow for targeted risk stratification and aid in delivery of future tailor

46 ion is to improve diagnostic classification, risk stratification and assignment of molecular, disease

47 approach was applied to define a multilayer risk stratification and better profile patient survival

48 ultiple biomarkers have been shown to refine risk stratification and can be considered for select men

49 This should lead to better risk stratification and clinical decision-making.

50 Also, 15-day posttransplant CMI risk stratification and CMI specific to the 65 kDa phosp

51 in-II type 1 receptor, did not contribute to risk stratification and could not explain the histology

52 esonance imaging (mpMRI) has transformed the risk stratification and diagnostic approach for suspecte

53 ecular features for early detection, disease risk stratification and directing targeted therapies.

54 in adipose tissue imaging for cardiovascular risk stratification and discuss how therapeutic targetin

55 diovascular disease has provided guidance on risk stratification and enhanced our knowledge on hither

56 thresholds can be identified and used to aid risk stratification and facilitate decision-making.Metho

57 cuss angiogenic biomarker assays for disease-risk stratification and for the development of therapeut

58 approximately 67, which provides a basis for risk stratification and genetic counseling.

59 litate functional precision medicine such as risk stratification and individually optimized therapeut

60 to incorporate frailty into the preoperative risk stratification and investigate strategies to suppor

61 istent approach and may have implications in risk stratification and long-term prognosis.

62 for exposed or infected health care workers, risk stratification and management strategies based on C

63 dnexal Reporting and Data System (O-RADS) US risk stratification and management system is designed to

64 ombining vWF-Ag levels with MELD-Na improves risk stratification and may help to prioritize organ all

65 , we describe the key features of diagnosis, risk stratification and modern paradigms in the treatmen

66 oendocrine neoplasms (NENs) is essential for risk stratification and optimal choice of therapy.

67 uring neutrophil-related changes may improve risk stratification and patient selection, a critical fi

68 ropathy (BKPyVAN), can be useful for patient risk stratification and possibly vaccine development.

69 ts is important for identifying novel genes, risk stratification and potential clinical applications.

70 treatment, providing an independent tool for risk stratification and precision medicine.

71 optimal management of associated conditions, risk stratification and prevention of complications, rec

72 abry disease (FD), but biomarkers could help risk stratification and prognosis.

73 Risk stratification and prophylactic measures have good

74 ing can also be applied to cancer screening, risk stratification and quantification of minimal residu

75 iratory assessments beyond 36 weeks improves risk stratification and should be considered when updati

76 culizumab prophylaxis based on pretransplant risk stratification and support the need for a rigorous

77 olecular diagnosis and potential markers for risk stratification and target therapy.

78 iome evaluation could assist with infectious risk stratification and that improved targeting of antib

79 iome evaluation could assist with infectious risk stratification and that improved targeting of antib

80 h-sensitivity cardiac troponin (hs-cTnl) for risk stratification and the early rule-out of myocardial

81 scle abnormalities may be used to facilitate risk stratification and the guidance of targeted strateg

82 s, the need for a multibiomarker approach to risk stratification and the role of sST2 as a guide to t

83 tant insights for models of patient-specific risk stratification and therapy planning.

84 >=100 pg/mL) can inform cardiovascular (CV) risk stratification and treatment decisions among adults

85 odel was converted into a scoring system for risk stratification and was evaluated in separate SA and

86 he diseases and other risk factors, improved risk stratification and, in particular for Brugada syndr

87 spective testing of both pathways may aid in risk-stratification and in immune monitoring.

88 modalities such as MRI and PET in diagnosis, risk stratification, and management of patients with car

89 This has applications for risk stratification, and may facilitate earlier consider

90 clonal evolution may inform surveillance and risk stratification, and may lead to the development of

91 se characterization, enable patient-specific risk stratification, and open new avenues for archetype-

92 f Alphabeta1-40 in CVD prognosis and patient risk stratification, and present the therapeutic interve

93 rmation, which may improve cancer diagnosis, risk stratification, and prevention.

94 nd benefits of chemoprophylaxis, discuss VTE risk stratification, and recommend which patients should

95 gated into a polygenic score, enable genomic risk stratification, and to test whether alcohol intake

96 n the general population, the actual burden, risk stratification, and treatment of the so-called arrh

97 volving supervised learning for diagnostics, risk stratification, and treatment simulation.

98 llary PH now guides point-of-care diagnosis, risk stratification, and treatment.

99 y and, when used in conjunction with current risk stratification approaches, can improve risk stratif

100 ostic work-up, genetic and family screening, risk stratification approaches, lifestyle modifications,

101 mework of European LeukemiaNet genetic-based risk stratification are discussed.

102 es, therapeutic recommendations, and medical risk stratifications are based on dedicated, strictly co

103 Clinical tools for prognostication and risk-stratification are needed.

104 arizes the current data guiding preoperative risk stratification as well as periprocedural management

105 perative Risk Evaluation II improved patient risk stratification, as assessed by the integrated discr

106 definite RHD and provides the first tool for risk stratification, assigning children with latent RHD

107 dissemination further improves DLBCL patient risk stratification at staging.

108 l, once externally validated, may facilitate risk stratification at term-equivalent age for early ide

109 utomated system, 'CognoSpeak', which enables risk stratification at the primary-secondary care interf

110 ntify the best performing classifier for PCa risk stratification based on mpMRI-derived radiomic feat

111 might lay the groundwork for an improved CRC risk stratification-based surveillance in IBD.

112 Fifteen-day CMI risk stratification better predicted CMV infection (81.3

113 RV indices provided additional risk stratification beyond biomarker strata; risk for de

114 o biomarkers should provide a firm basis for risk stratification, both in clinical practice and in re

115 Beyond risk stratification, CAC has been shown to identify high

116 In patients with vascular disease, further risk stratification can identify higher-risk patients (>

117 analysis, the model showed independent high risk-stratification capability (P<0.001), even in subgro

118 Implementation of risk stratification coupled with specific strategies for

119 ively, comparing favourably to international risk-stratification criteria.

120 This may have implications for psychiatry in risk stratification, early recognition, diagnostics, pre

121 gical staging, as well as inconsistencies in risk stratification, endoscopic resection and schedules

122 ary Hypertension Registry approach, improved risk stratification for 1-year mortality.Conclusions: Ca

123 under intense scrutiny within the context of risk stratification for a variety of cancers.

124 Diastolic function grading might improve risk stratification for AD.

125 sist in improvement of functional status and risk stratification for age-related chronic diseases.

126 HPV-related biomarkers provide long-term risk stratification for anal precancers.

127 grading of diastolic function might improve risk stratification for arrhythmic death.

128 We show that PRS have potential for risk stratification for cancers of breast, colon and pro

129 ectronic health records to provide automated risk stratification for cardiovascular diseases.

130 us, screening for cardiovascular disease and risk stratification for cardiovascular events constitute

131 Sophisticated risk stratification for children with RMS incorporates v

132 splantation and to improve patient selection/risk stratification for clinical trials were also discus

133 Models can assist with risk stratification for clinical trials.

134 ting biomarkers can facilitate diagnosis and risk stratification for complex conditions such as heart

135 ctive accuracy for incident CAD and improved risk stratification for only a small proportion of indiv

136 markers could provide an automatic method of risk stratification for progression to vision-threatenin

137 sis with this mutation may be sufficient for risk stratification for SCD.

138 t ventricular outflow tract obstruction, and risk stratification for sudden cardiac death.

139 affected by aneurysm formation could aid in risk stratification for the formation of BTAs in high-ri

140 pregnancy risk factors allow development of risk-stratification for SGA.

141 Before considering the use of NT-proBNP for risk stratification, further research should untangle wh

142 Improvements in risk stratification have already been seen through the i

143 Preoperative surgical evaluation and risk stratification have traditionally centered on optim

144 iac troponin has the potential to facilitate risk stratification, help make decisions about when to u

145 Various prognostic models exist for risk stratification; however, those are based on solely

146 utations as a necessary requirement for high-risk stratification in addition to exceeding the del17p

147 The updated guidelines provide a risk stratification in BL hypersensitivity according to

148 a potential role in disease phenotyping and risk stratification in chronic obstructive pulmonary dis

149 HLA typing or rs2856830 genotyping improves risk stratification in clinical practice or trials.

150 inical management of patients and facilitate risk stratification in clinical trials.

151 ap and easy-to-use triage tool for the early risk stratification in COVID-19 patients presenting in E

152 multicenter prospective observational ISAR (Risk Stratification in End-Stage Renal Disease) study, d

153 ay be a novel diagnostic tool to optimize CV risk stratification in ESRD and other high-risk CV cohor

154 epresents a promising strategy for enhancing risk stratification in HFpEF.

155 enetic mechanisms of PCa and facilitates PCa risk stratification in Japanese population.

156 Improving cytomegalovirus (CMV) immune-risk stratification in kidney transplantation is highly

157 profiling may be a promising tool for rapid risk stratification in neonatal encephalopathy.

158 upports further evaluation of cardiac MRI in risk stratification in PAH.

159 emental to conventional clinical factors for risk stratification in patients undergoing IE surgery.

160 velop objective frailty assessment tools for risk stratification in patients with advanced heart dise

161 d provide prognostic information and improve risk stratification in patients with aortic stenosis (AS

162 erum HLA antibody analysis for pretransplant risk stratification in patients with DSA.

163 ameters are easy to assess and could help in risk stratification in patients with unruptured PCoA ane

164 Alloimmune risk stratification in renal transplantation has lacked

165 Ab) for donor-recipient matching and patient risk stratification in renal transplantation is the sing

166 artery calcium has the potential to improve risk stratification in select individuals beyond clinica

167 tablished, AF might be integrated to improve risk stratification in some specific phenotypes.

168 (HL), but the role of pretreatment clinical risk stratification in the context of positron emission

169 rategies, but reliable tools are lacking for risk stratification in the population.

170 Accurate risk stratification in this group is paramount to optimi

171 unlikely to improve atherothrombotic events risk stratification in this population.

172 simple single-examination-based approach for risk stratification in this subset of patients.(C) RSNA,

173 This issue has precluded the use of MTV for risk stratification in trials and clinical practice.

174 polygenic risk score (PRS) enables effective risk stratification in unselected glaucoma cases and mod

175 indings allowed us to develop a strategy for risk stratification in which HVPG response was measured

176 Traditional methods of risk stratification include histologic grade and hormone

177 nd epigenetic modulating drugs will increase risk stratification, increase accessibility for DNA targ

178 errations at FL diagnosis with CGAT improves risk stratification independent of known clinical parame

179 tively, and PRS was an independent effective risk stratification indicator beyond age and smoking pac

180 sment are primarily used and integrated with risk stratification indices to establish optimal treatme

181 Risk stratification is critical in heart failure (HF) an

182 Early risk stratification is essential for in-hospital managem

183 Risk stratification is essential for the delivery of opt

184 al cardiopulmonary disease; therefore, rapid risk stratification is necessary to make decisions of ap

185 on have heterogeneous outcomes, and accurate risk stratification is necessary to optimize patient sel

186 Better risk stratification is needed to predict which women are

187 ronavirus disease 2019 (COVID-19) for proper risk stratification, isolation strategies, and treatment

188 omponents such as clinical prediction tools, risk stratification, laboratory tests, and imaging widel

189 Thus, improved risk stratification methods are needed, as is a deeper u

190 Risk stratification methods to identify patients with in

191 Most risk stratification methods use expert opinion to identi

192 function, and provide complementary clinical risk stratification metrics for management of these pati

193 ta imputation can be used to obtain improved risk stratification metrics, particularly for patients w

194 we have developed and clinically verified a risk stratification model based on a second TE biopsy co

195 ies in preimplantation embryos and develop a risk stratification model that can help post-test geneti

196 and malignant thyroid nodules by offering a risk stratification model.

197 d biomarkers did not only outperform current risk stratification models but may also reflect importan

198 studies, and diagnostic accuracy studies of risk stratification models in women without preexisting

199 rtant aspect of widespread adoption of newer risk-stratification models.

200 ataract cases using the New Zealand Cataract Risk Stratification (NZCRS) scoring system.

201 Preoperative risk stratification of 500 consecutive cataract cases us

202 TTV is a prospective biomarker for risk stratification of acute biopsy-proven alloreactivit

203 Improved risk stratification of acute heart failure in the emerge

204 Conclusion: (18)F-FDG PET is useful for risk stratification of all NEN grades and is superior to

205 also be considered as an important factor in risk stratification of cardiovascular disease for women.

206 vital role in the diagnosis, management, and risk stratification of cardiovascular diseases, is uncle

207 d before ultimately incorporating high-CK in risk stratification of CLL.

208 described for the prognosis, diagnosis, and risk stratification of CVDs.

209 diac magnetic resonance (CMR) permits robust risk stratification of discharged ST-segment-elevation m

210 Accurate risk stratification of early heart transplant failure is

211 ultiplex PCR assay may prove helpful for the risk stratification of hematology patients with ARF.

212 This mortality risk model allows early risk stratification of hospitalized patients with COVID-

213 bles, 2 scoring systems were constructed for risk stratification of ISM at diagnosis with significant

214 need for improved methods for detection and risk stratification of myocarditis associated with immun

215 In the selection of therapy and for risk stratification of NEN patients, (18)F-FDG PET statu

216 rognostic value of (18)F-FDG PET imaging for risk stratification of NENs and compare it with tumor gr

217 lights the importance of clinical frailty in risk stratification of older ICU patients with suspected

218 recise noninvasive method to detect iron for risk stratification of patients and therapy evaluation.

219 Recalibration significantly improved risk stratification of patients into clinical risk categ

220 udies have now documented factors that allow risk stratification of patients with cancer in order to

221 w that SARS-CoV-2 viral loads may aid in the risk stratification of patients with COVID-19, and there

222 Background Risk stratification of patients with low-gradient (LG) s

223 Although risk stratification of patients with MB based on molecul

224 Little is known about the risk stratification of patients with myocarditis undergo

225 l role in the diagnosis, categorization, and risk stratification of patients with pulmonary hypertens

226 LV GLS may therefore be useful in the risk stratification of patients with secondary MR.

227 fferent molecular biomarkers may improve the risk stratification of patients.

228 r are promising biomarker candidates for the risk stratification of septic acute kidney injury patien

229 al implications for decision-making based on risk stratification of severe COVID-19 patients.

230 nostic algorithms are suggested depending on risk stratification of the patient into high and low ris

231 nostic algorithms are suggested depending on risk stratification of the patient into high and low ris

232 However, the long-term performance and risk stratification of these biomarkers are unknown.

233 classification should be incorporated in the risk stratification of these patients as well as in futu

234 HFpEF; its use may help refining the routine risk stratification of these patients on top of well-est

235 des the framework for accurate diagnosis and risk stratification of this disease, and the rationale f

236 ng data from the CRUSADE Registry (Can Rapid Risk Stratification of Unstable Angina Patients Suppress

237 Risk stratification of women based on multidimensional r

238 ng to cervical cancer, which could influence risk stratification of women when screening for cervical

239 in (hs-cTn) concentrations for diagnosis and risk-stratification of syncope is incompletely understoo

240 te vWF-Ag as an adjunct surrogate marker for risk stratification on the waiting list for OLT.

241 UP) grade, and clinical stage as traditional risk stratification parameters.

242 incidence with subsequently improved disease-risk stratification, particularly when considering patie

243 s undergoing heart transplantation for early risk stratification, patient monitoring, and clinical tr

244 o 2.6% in baseline phase and 1.4% in a prior risk stratification phase.

245 uggest a role for measuring Gal-3 levels for risk stratification post-MI.

246 descending coronary artery (LAD) expands the risk stratification potential of stress echocardiography

247 e used for earlier identification of sepsis, risk stratification/prognostication, and/or guidance of

248 Clinical-risk stratification provided prognostic information that

249 r patients' age, sex, pseudoexfoliation, and risk stratification remained significantly predictive fo

250 or first-line imaging of MPeM, diagnosis and risk stratification remains challenging.

251 f hematopoietic transplantation, yet patient risk stratification remains difficult, and prognostic bi

252 Whereas TTFT risk stratification remains similar over time, TTP and O

253 s into pathogenesis, potential drug targets, risk stratification, response to therapy and vaccination

254 ng logistic regression analysis, a validated risk stratification score was developed.

255 Risk-stratification screening for SGA has been proposed

256 Risk stratification seems to reduce intraoperative phaco

257 on, pre-treatment cardiac evaluation, and CV risk stratification should be considered within the CAR

258 genotype-specific approach for diagnosis and risk stratification should be used.

259 Better risk stratification strategies are needed to enhance cli

260 s into its pathogenesis as well as improving risk stratification strategies.

261 Limited data exist on rapid risk-stratification strategies using the U.S.

262 Chronic lymphocytic leukemia (CLL) risk stratification studies typically focus on time to f

263 morphologic parameters for surveillance and risk stratification.Supplemental material is available f

264 Our proposed risk stratification system also showed acceptable 1-year

265 We need a better risk stratification system for the increasing number of

266 We developed a risk stratification system from known prognostic factors

267 nto the pLGG molecular landscape and a novel risk stratification system with the potential to revolut

268 w diagnostic pathway will affect the current risk-stratification system and explore future challenges

269 osarcoma soft-tissue sarcoma (NRSTS), but no risk stratification systems exist and the standard of ca

270 Background Risk stratification systems for thyroid nodules are ofte

271 Standardized and robust risk-stratification systems for patients with hepatocell

272 of scar heterogeneity and provides a better risk stratification than LGE presence and its extent in

273 Genetic profiling is one approach to risk stratification that has been extensively validated

274 For risk stratification, the O-RADS US system recommends six

275 ctDNA assessment for early risk stratification, therapy monitoring, and early relap

276 imit of detection (<2 ng/L) and an optimized risk stratification threshold (<5 ng/L) using the Abbott

277 Use of risk stratification thresholds for hs-cTnl identify pati

278 We evaluate the safety and effectiveness of risk stratification thresholds in patients with suspecte

279 demonstrate the feasibility of preoperative risk stratification through the use of an IH risk calcul

280 to BCG therapy could improve biomarkers for risk stratification to align therapy with biological ris

281 arge, and a clinically meaningful metric for risk stratification to guide interventions remains a cha

282 state cancer has been proposed as a means of risk stratification to identify those for whom prostate-

283 de precision measures of metabolic health in risk stratification to interrupt CVD at its earliest sta

284 ission and laboratory data may be useful for risk stratification to predict severe AKI.

285 ng ultrasound (LUS) is a promising pragmatic risk stratification tool in COVID-19.

286 core, we demonstrate a clinically applicable risk stratification tool with a binary output for risk o

287 ial calcification has emerged as a potential risk stratification tool.

288 nslate this prediction model into a clinical risk-stratification tool, we identified high- and low-ri

289 definitions and limitations of commonly used risk stratification tools for PE are reviewed.

290 syndrome is heterogeneous, with a paucity of risk stratification tools to assist with trial design.

291 Improved surveillance algorithms and risk stratification tools, studies of clonal evolution,

292 erapeutic efficacy may have a huge impact on risk stratification, treatment, and ultimately outcome f

293 Risk stratification using a novel clinical risk score fo

294 However, risk-stratification using the FRS has never been investi

295 Appropriate risk stratification utilizing clinical, pathological and

296 With respect to pretransplant risk stratification, we propose a signal-to-background r

297 of the highest Gleason pattern) may improve risk stratification when added to standard clinical para

298 ABSI, complements BMI and enables efficient risk stratification, which could facilitate personalisat

299 e key topics including the implementation of risk stratification with minimal residual disease measur

300 Risk stratification with this nomogram could improve del